about
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroExpression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.ERCC5 is a novel biomarker of ovarian cancer prognosis.
P50
Q21195212-E6080228-439E-4397-97FE-806ECE2CCBAAQ27851620-863777B7-6A42-48DE-9DE2-E87DE01B7FA7Q27852487-C4166855-E698-4617-8D3B-3A72AF3AD666Q34041321-63D3CA14-79CA-4F12-A17B-D80F2C735861Q34129528-23B1B5EC-8BC6-4EE3-B9C3-C368521D2A61Q34736974-C2EEEFE7-2713-4AB4-80CA-ED622180E3CCQ37066536-B14F7BB5-E348-4AB3-94CD-E3AE788F1CADQ37657171-5F056169-DBC7-47E0-B4C8-8A25DE1BA66CQ38289922-74D08257-5251-4DF6-8453-C4EB09EEBE47
P50
description
onderzoeker
@nl
name
Charles Ginther
@ast
Charles Ginther
@en
Charles Ginther
@es
Charles Ginther
@sl
type
label
Charles Ginther
@ast
Charles Ginther
@en
Charles Ginther
@es
Charles Ginther
@sl
prefLabel
Charles Ginther
@ast
Charles Ginther
@en
Charles Ginther
@es
Charles Ginther
@sl